Suchergebnisse - "Oza, Amit M"

PubPharm (19)

1

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer : final results from Study 10

enthalten in: British journal of cancer | 2023

von Kristeleit, R. | Drew, Y. | Oza, A. | +13

2

Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Oza, A.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

3

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

4

ATHENA (GOG-3020/ENGOT-ov45) : a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2021

von Monk, B. | Coleman, R. | Fujiwara, K. | +18

5

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

enthalten in: Gynecologic oncology | 2021

von Swisher, E. | Kristeleit, R. | Oza, A. | +19

6

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

enthalten in: JAMA oncology | 2021

von Kwan, T. | Oza, A. | Tinker, A. | +18

CommentIn: JAMA Oncol. 2021 Dec 1;7(12):1763-1765. - PMID 34647967

7

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial : The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety

enthalten in: Cancer medicine | 2021

von Oaknin, A. | Oza, A. | Lorusso, D. | +21

8

Rucaparib maintenance treatment for recurrent ovarian carcinoma : the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2021

von Clamp, A. | Lorusso, D. | Oza, A. | +20

CommentIn: Int J Gynecol Cancer. 2021 Jul;31(7):959-960. - PMID 34103387

9

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

enthalten in: Gynecologic oncology | 2021

von Konecny, G. | Oza, A. | Tinker, A. | +23

10

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

enthalten in: Nature communications | 2021

von Swisher, E. | Kwan, T. | Oza, A. | +31